Category: Family

Metabolic syndrome abdominal obesity

Metabolic syndrome abdominal obesity

Thank you for Obesitg nature. National heart, lung and blood institute; Br Med J : — Associations with glucose tolerance, plasma insulin, and lipoprotein levels.


Abdominal obesity, adiposopathy, inflammation and cardiovascular disease risk management

Metabolic syndrome abdominal obesity -

Molecular mechanisms of insulin resistance and the role of the adipocyte. Havel, P. Control of energy homeostasis and insulin action by adipocyte hormones: leptin, acylation stimulating protein, and adiponectin.

Energy partitioning in gluteal-femoral fat: does the metabolic fate of triglycerides affect coronary heart disease risk? Miranda, P. Metabolic syndrome: definition, pathophysiology, and mechanisms.

Heart J. Gavrilova, O. Surgical implantation of adipose tissue reverses diabetes in lipoatrophic mice. Article CAS PubMed PubMed Central Google Scholar. Kim, J. Garg, A. Lipodystrophies: rare disorders causing metabolic syndrome.

North Am. Danforth, E. Failure of adipocyte differentiation causes type II diabetes mellitus? Nature Genet. Miyazaki, Y. Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. Wilson, P. Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus.

Circulation , — Laaksonen, D. Metabolic syndrome and development of diabetes mellitus: application and validation of recently suggested definitions of the metabolic syndrome in a prospective cohort study. Stern, M. Identification of persons at high risk for type 2 diabetes mellitus: do we need the oral glucose tolerance test?

Klein, B. Components of the metabolic syndrome and risk of cardiovascular disease and diabetes in beaver dam. Diabetes Care 25 , — Macchia, A. A clinically practicable diagnostic score for metabolic syndrome improves its predictivity of diabetes mellitus: the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico GISSI -Prevenzione scoring.

e17 UK Prospective Diabetes Study UKPDS Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes UKPDS Libby, P.

Diabetic macrovascular disease: the glucose paradox? Laakso, M. Hyperglycemia and cardiovascular disease in type 2 diabetes.

Diabetes 48 , — Definition of metabolic syndrome. Golden, S. Risk factor groupings related to insulin resistance and their synergistic effects on subclinical atherosclerosis: the atherosclerosis risk in communities study.

Prediction of coronary heart disease using risk factor categories. Circulation 97 , — Wannamethee, S. Metabolic syndrome vs Framingham Risk Score for prediction of coronary heart disease, stroke, and type 2 diabetes mellitus.

Diabetes Care 27 , — Assmann, G. Simple scoring scheme for calculating the risk of acute coronary events based on the year follow-up of the prospective cardiovascular Munster PROCAM study.

Girman, C. Lamarche, B. Fasting insulin and apolipoprotein B levels and low-density lipoprotein particle size as risk factors for ischemic heart disease.

Hegele, R. Insulin resistance in human partial lipodystrophy. Barrett-Connor, E. Cigarette smoking and increased central adiposity. Shimokata, H. Studies in the distribution of body fat. Effects of cigarette smoking.

Insulin resistance and compensatory hyperinsulinemia: the key player between cigarette smoking and cardiovascular disease? Pouliot, M. Visceral obesity in men. Associations with glucose tolerance, plasma insulin, and lipoprotein levels.

Diabetes 41 , — Treatment of obesity: need to focus on high risk abdominally obese patients. Article PubMed PubMed Central Google Scholar.

Jorgensen, M. Obesity and central fat pattern among Greenland Inuit and a general population of Denmark Inter99 : relationship to metabolic risk factors. Ross, R. Reduction in obesity and related comorbid conditions after diet-induced weight loss or exercise-induced weight loss in men.

A randomized, controlled trial. Orchard, T. The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program randomized trial. Katzmarzyk, P. Targeting the metabolic syndrome with exercise: evidence from the HERITAGE Family Study.

Sports Exerc. Dumont, M. Effect of a six month gemfibrozil treatment and dietary recommendations on the metabolic risk profile of visceral obese men. Leon, A. Response of blood lipids to exercise training alone or combined with dietary intervention.

Waist girth does not predict metabolic complications in severely obese men. Diabetes Care 29 , — Hypertriglyceridemic waist. A marker of the atherogenic metabolic triad hyperinsulinemia, hyperapolipoprotein B, small, dense LDL in men?

Underwood, P. Cardiovascular risk, the metabolic syndrome and the hypertriglyceridaemic waist. Kahn, H. Metabolic risks identified by the combination of enlarged waist and elevated triacylglycerol concentration.

Lean, M. Waist circumference as a measure for indicating need for weight management. Zhu, S. Waist circumference and obesity-associated risk factors among whites in the third National Health and Nutrition Examination Survey: clinical action thresholds.

Beckley, E. New ADA initiative moves beyond 'metabolic syndrome'. DOC News 3 , 1—3 Preventing cardiovascular disease and diabetes: a call to action from the American Diabetes Association and the American Heart Association.

From CVD risk to cardiometabolic risk. Presented at the Symposium of the International Chair on Cardiometabolic Risk. XIV International Symposium on Atherosclerosis Rome, 18—22 June Visceral adiposity.

Presented at the 66th Scientific Sessions, American Diabetes Association Washington, DC, 9—13 June Bouchard, C. The response to long-term overfeeding in identical twins. Download references. The work of the authors has been supported by research grants from the Canadian Institutes of Health Research, the Canadian Diabetes Association, the Heart and Stroke Foundation and by the Foundation of the Québec Heart Institute.

is Scientific Director of the International Chair on Cardiometabolic Risk, which is supported by an unrestricted grant from Sanofi Aventis awarded to Université Laval. Québec Heart Institute, Hôpital Laval Research Centre, chemin Sainte-Foy, Pavilion Marguerite-D'Youville, 4th Floor, Quebec City, QC G1V 4G5, Canada.

Division of Kinesiology, Department of Social and Preventive Medicine, Université Laval, Quebec City, QC G1K 7P4, Canada. You can also search for this author in PubMed Google Scholar. Reprints and permissions. Després, JP. Abdominal obesity and metabolic syndrome. Download citation.

Published : 13 December Issue Date : 14 December Anyone you share the following link with will be able to read this content:. Sorry, a shareable link is not currently available for this article. Provided by the Springer Nature SharedIt content-sharing initiative.

European Journal of Clinical Nutrition European Journal of Medical Research By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily. Skip to main content Thank you for visiting nature. nature review articles article. Abstract Metabolic syndrome is associated with abdominal obesity, blood lipid disorders, inflammation, insulin resistance or full-blown diabetes, and increased risk of developing cardiovascular disease.

Access through your institution. Buy or subscribe. Change institution. Learn more. Figure 1: The lipid overflow—ectopic fat model. Figure 2: Factors contributing to global cardiometabolic risk.

References Grundy, S. Article CAS PubMed Google Scholar Grundy, S. Article CAS Google Scholar Moller, D. Article CAS PubMed Google Scholar Sattar, N. Article CAS PubMed Google Scholar Eckel, R. Article CAS PubMed Google Scholar Reaven, G. Article CAS PubMed Google Scholar Ferrannini, E. Article CAS Google Scholar Gale, E.

Article PubMed Google Scholar Kahn, R. Article PubMed Google Scholar Reaven, G. Article CAS PubMed Google Scholar Alberti, K. Article CAS PubMed Google Scholar Executive Summary of The Third Report of The National Cholesterol Education Program NCEP Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults Adult Treatment Panel III.

Article PubMed Google Scholar Galassi, A. Article CAS PubMed Google Scholar Mokdad, A. Article Google Scholar Zimmet, P. Article ADS CAS PubMed Google Scholar Astrup, A. Article CAS Google Scholar Shafrir, E. CAS PubMed Google Scholar Pincock, S. Article PubMed Google Scholar Després, J. Article PubMed Google Scholar Albu, J.

Article CAS PubMed Google Scholar WHO Expert Consultation. Article CAS Google Scholar Lovejoy, J. Article CAS PubMed Google Scholar Conway, J. Article CAS PubMed Google Scholar Abbasi, F. Article CAS PubMed Google Scholar Després, J. Article PubMed CAS Google Scholar Björntorp, P. Article PubMed Google Scholar Kissebah, A.

Article CAS PubMed Google Scholar Lebovitz, H. Article PubMed Google Scholar Mittelman, S. Article CAS PubMed Google Scholar Mauriège, P. Article PubMed Google Scholar Bergman, R. Article CAS Google Scholar Jensen, M. Article MathSciNet CAS Google Scholar Weisberg, S. Article CAS PubMed PubMed Central MathSciNet Google Scholar Yudkin, J.

Article CAS PubMed Google Scholar Tsimikas, S. Article CAS PubMed Google Scholar Lemieux, I. Article CAS PubMed Google Scholar Maeda, K.

Article CAS PubMed Google Scholar Scherer, P. Article CAS PubMed Google Scholar Côté, M. Article PubMed CAS Google Scholar Berg, A. Article CAS PubMed Google Scholar Matsuzawa, Y. Article CAS Google Scholar Lemieux, I.

Google Scholar Hotamisligil, G. Article CAS PubMed Google Scholar Havel, P. Article CAS PubMed Google Scholar Miranda, P. Article CAS PubMed Google Scholar Gavrilova, O. Further, apo B levels and small, dense LDL particles have been shown to segregate independently in families with FCHL FCHL is a subtype of the metabolic syndrome, with higher apo B levels.

The identification of FCHL patients at high risk for CAD within the large population of individuals with the metabolic syndrome can help identify individuals as candidates for aggressive lipid-lowering interventions.

The metabolic syndrome is a common population trait comprised of a heterogeneous group of oligogenic disorders, such as DM2 and familial combined hyperlipidemia see Fig.

The identification of these metabolic syndrome subtypes by measuring fasting glucose and apo B can help target these high risk patients for lipid-lowering therapy. Patients with the metabolic syndrome should be screened for DM2, as individuals with DM2 and the metabolic syndrome are at high risk for CAD.

Current guidelines recommend that patients with DM2 should be aggressively treated for dyslipidemia with the goal to maintain LDL below 2. Apo B levels increase with age; therefore, age-appropriate apo B levels must be used in diagnosis Several large prospective studies have shown that the apo B level is a better predictor of future cardiovascular events than the LDL cholesterol level 45 , 71 , Recently, the Apolipoprotein-Related Mortality Risk Study published prospective data in , men and women and found that the total apo B level was a better predictor of future CAD risk than LDL cholesterol Importantly, they also found that apo B was a better predictor of CAD risk in individuals with low LDL levels, supporting the idea that patients with low LDL cholesterol levels and increased quantities of small, dense atherogenic particles VLDL, IDL, and LDL are at risk for CAD.

Apo B levels by age and gender mean and 90th percentile. To convert apo B values to grams per liter, divide by In addition to apo B, the measurement of non-HDL cholesterol total cholesterol minus HDL cholesterol can be used to assess the quantity of atherogenic apo B-containing lipoproteins VLDL, IDL, and LDL.

Some investigators have proposed that non-HDL cholesterol could replace the LDL measure in patients with hypertriglyceridemia dyslipidemia with DM2 or FCHL , because these patients have more cholesterol in VLDL particles, and LDL cholesterol alone can underestimate their CAD risk The current NCEP guidelines recommend a non-HDL cholesterol goal of less than 3.

Total apo B and non-HDL cholesterol levels are generally highly correlated, but less so at higher triglyceride levels. Comprehensive treatment of patients with the metabolic syndrome has recently been described in detail The treatment of the dyslipidemia of the metabolic syndrome should be focused on lowering LDL and apo B and increasing HDL.

Statin treatment has been shown to reduce cardiovascular events in persons with low LDL cholesterol levels at baseline The percent reduction in LDL cholesterol and apo B by statin medications is similar, but apo B may be a better marker of treatment efficacy in metabolic syndrome patients with normal LDL cholesterol Although LDL cholesterol has remained the primary target of lipid-lowering therapy, raising HDL levels is now an important secondary target to reduce CAD risk 5.

Combination lipid-lowering therapy is frequently needed to treat the dyslipidemia of the metabolic syndrome increased triglyceride, reduced HDL, and small, dense LDL particles , if lifestyle changes weight loss and exercise are inadequate. Nicotinic acid and fibric acid derivatives both act to reduce triglyceride and increase HDL cholesterol.

They are frequently used with statin medications. Although fibrate monotherapy lowers plasma triglyceride levels, it can lead to increases in LDL levels. Bile acid resin binders lower LDL cholesterol levels, but can increase triglyceride levels in individuals susceptible to hypertriglyceridemia.

Although niacin is an inexpensive monotherapeutic agent that corrects the dyslipidemia of the metabolic syndrome, it may increase glucose levels in some patients Several groups have recently shown that niacin use in diabetic individuals was safe and effective, resulting in only a transient worsening of glycemic control 78 — The decision to initiate lipid-lowering therapy in nondiabetic individuals with the metabolic syndrome can be difficult using current guidelines, as LDL levels may underestimate CAD risk in this population.

The large population of individuals with the metabolic syndrome appears to be comprised of a heterogeneous group of disorders, and the identification of disease subtypes at high risk for CAD can help identify individuals as candidates for aggressive lipid-lowering interventions.

Two subgroups of patients with the metabolic syndrome, those with DM2 or FCHL, are at particularly high risk for premature CAD. FCHL is characterized by the metabolic syndrome in addition to a disproportionate elevation of apo B levels. The measurement of fasting glucose and apo B in addition to the fasting lipid profile can help to estimate CAD risk and guide treatment decisions in patients with the metabolic syndrome.

This work was supported by NIH Grants HL, HL, and DK and K23 Award RR to M. and by University of Washington General Clinical Research Center MRR Larsson B , Svardsudd K , Welin L , Wilhelmsen L , Bjorntorp P , Tibblin G Abdominal adipose tissue distribution, obesity, and risk of cardiovascular disease and death: 13 year follow up of participants in the study of men born in Br Med J : — Google Scholar.

Lapidus L , Bengtsson C , Larsson B , Pennert K , Rybo E , Sjostrom L Distribution of adipose tissue and risk of cardiovascular disease and death: a 12 year follow up of participants in the population study of women in Gothenburg, Sweden. Ducimetiere P , Richard J , Cambien, F The pattern of subcutaneous fat distribution in middle-aged men and the risk of coronary heart disease: the Paris Prospective Study.

Int J Obes 10 : — Alberti KG , Zimmet, PZ Definition, diagnosis and classification of diabetes mellitus and its complications. Diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabetes Med 15 : — National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults Executive summary of The third report of the National Cholesterol Education Program NCEP Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults Adult Treatment Panel III.

JAMA : — Fujimoto W , Abbate S , Kahn S , Hokanson J , Brunzell J The visceral adiposity syndrome in Japanese-American men. Obes Res 2 : — Ruderman N , Chisholm D , Pi-Sunyer X , Schneider S The metabolically obese, normal-weight individual revisited.

Diabetes 47 : — Borkan GA , Hults DE , Gerzof SG , Robbins AH , Silbert, CK Age changes in body composition revealed by computed tomography.

J Gerontol 38 : — Am J Clin Nutr 58 : — J Clin Endocrinol Metab 86 : — Haarbo J , Marslew U , Gotfredsen A , Christiansen C Postmenopausal hormone replacement therapy prevents central distribution of body fat after menopause. Metabolism 40 : — Carr MC, Brunzell JD, Increased hepatic lipase activity and intraabdominal fat across the transition from pre- to postmenopause.

Program of the 85th Annual Meeting of The Endocrine Society, Philadelphia, PA, , p Abstact P Wajchenberg BL Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome. Endocr Rev 21 : — Perusse L , Despres JP , Lemieux S , Rice T , Rao DC , Bouchard C Familial aggregation of abdominal visceral fat level: results from the Quebec family study.

Metabolism 45 : — Fujimoto WY The growing prevalence of non-insulin-dependent diabetes in migrant Asian populations and its implications for Asia. Diabetes Res Clin Pract 15 : — The Insulin Resistance Atherosclerosis Study.

Diabetes 45 : — Marsh JB Lipoprotein metabolism in obesity and diabetes: insights from stable isotope kinetic studies in humans.

Nutr Rev 61 : — McNamara J , Campos H , Ordovas J , Peterson J , Wilson P , Schaefer E Effect of gender, age, and lipid status on low density lipoprotein subfraction distribution. Results of the Framingham Offspring Study.

Arteriosclerosis 7 : — Arteriosclerosis 9 : — Austin MA , King MC , Vranizan KM , Krauss RM Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk.

Circulation 82 : — Austin M , Breslow J , Hennekens C , Buring J , Willett W , Krauss, R Low-density lipoprotein subclass patterns and risk of myocardial infarction.

Stampfer MJ , Krauss RM , Ma J , Blanche PJ , Holl LG , Sacks, FM , Hennekens CH A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction. Lamarche B , Tchernof A , Moorjani S , Camtin B , Dagenais G , Lupien P , Despres J-P Small, dense low-density lipoprotein particles as a predictor of risk of ischemic heart disease in men: prospective results from the Quebec Cardiovascular Study.

Circulation 95 : 69 — Tornvall P , Karpe F , Carlson L , Hamsten A Relationship of low density lipoprotein subfractions to angiographically defined coronary artery disease in young survivors of myocardial infarction.

Atherosclerosis 90 : 67 — Campos H , Genest JJ , Blijlevens E , McNamara JR , Jenner JL , Ordovas JM , Wilson PW , Schaefer EJ Low density lipoprotein particle size and coronary artery disease.

Arterioscler Thromb 12 : — Gardner CD , Fortmann SP , Krauss RM Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women.

Zambon A , Hokanson JE , Brown BG , Brunzell JD Evidence for a new pathophysiological mechanism for coronary artery disease regression: hepatic lipase-mediated changes in LDL density. Circulation 99 : — Bjornheden T , Babyi A , Bondjers G , Wiklund O Accumulation of lipoprotein fractions and subfractions in the arterial wall, determined in an in vitro perfusion system.

Atherosclerosis : 43 — Hurt-Camejo E , Camejo G , Rosengren B , Lopez F , Wiklund, O , Bondjers G Differential uptake of proteoglycan-selected subfractions of low density lipoprotein by human macrophages. J Lipid Res 31 : — Chait A , Brazg R , Tribble D , Krauss R Susceptibility of small, dense, low-density lipoproteins to oxidative modification in subjects with the atherogenic lipoprotein phenotype, pattern B.

Tribble DL , Rizzo M , Chait A , Lewis DM , Blanche PJ , Krauss RM Enhanced oxidative susceptibility and reduced antioxidant content of metabolic precursors of small, dense low-density lipoproteins.

Am J Med : — Santamarina-Fojo S , Haudenschild C , Amar M The role of hepatic lipase in lipoprotein metabolism and atherosclerosis. Curr Opin Lipidol 9 : — Eschwege E , Richard JL , Thibult N , Ducimetiere P , Warnet JM , Claude JR , Rosselin GE Coronary heart disease mortality in relation with diabetes, blood glucose and plasma insulin levels.

The Paris Prospective Study, ten years later. Horm Metab Res 15 Suppl : 41 — Despres JP , Moorjani S , Lupien PJ , Tremblay A , Nadeau A , Bouchard C Regional distribution of body fat, plasma lipoproteins, and cardiovascular disease.

Arteriosclerosis 10 : — Isomaa B , Almgren P , Tuomi T , Forsen B , Lahti K , Nissen M , Taskinen MR , Groop L Cardiovascular morbidity and mortality associated with the metabolic syndrome.

Diabetes Care 24 : — Lakka HM , Laaksonen DE , Lakka TA , Niskanen LK , Kumpusalo E , Tuomilehto J , Salonen JT The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men.

Ford ES , Giles WH , Dietz WH Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. Park YW , Zhu S , Palaniappan L , Heshka S , Carnethon MR , Heymsfield SB The metabolic syndrome: prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, — Arch Intern Med : — Alexander CM , Landsman PB , Teutsch SM , Haffner SM NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older.

Diabetes 52 : — Mosca L , Appel LJ , Benjamin EJ , Berra K , Chandra-Strobos N , Fabunmi RP , Grady D , Haan CK , Hayes SN , Judelson DR , Keenan NL , McBride P , Oparil S , Ouyang P , Oz MC , Mendelsohn ME , Pasternak RC , Pinn VW , Robertson RM , Schenck-Gustafsson K , Sila CA , Smith Jr SC , Sopko G , Taylor AL , Walsh BW , Wenger NK , Williams CL Evidence-based guidelines for cardiovascular disease prevention in women.

Circulation : — Genest JJ , McNamara JR , Salem DN , Schaefer EJ Prevalence of risk factors in men with premature coronary artery disease. Am J Cardiol 67 : — Am J Cardiol 93 : — Lamarche B , Moorjani S , Lupien PJ , Cantin B , Bernard PM , Dagenais GR , Despres JP Apolipoprotein A-I and B levels and the risk of ischemic heart disease during a five-year follow-up of men in the Quebec cardiovascular study.

Circulation 94 : — Reardon MF , Nestel PJ , Craig IH , Harper RW Lipoprotein predictors of the severity of coronary artery disease in men and women. Circulation 71 : — Walldius G , Jungner I , Holme I , Aastveit AH , Kolar W , Steiner E High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction AMORIS study : a prospective study.

Lancet : — Sniderman AD , Scantlebury T and Cianflone K Hypertriglyceridemic hyperapob: the unappreciated atherogenic dyslipoproteinemia in type 2 diabetes mellitus.

Ann Intern Med : — Bonora E , Kiechl S , Willeit J , Oberhollenzer F , Egger G , Bonadonna RC , Muggeo M Metabolic syndrome: epidemiology and more extensive phenotypic description.

Cross-sectional data from the Bruneck Study. Int J Obes Relat Metab Disord 27 : — Haffner SM Dyslipidemia management in adults with diabetes.

Diabetes Care 27 Suppl 1 : S68 — S Hopkins PN , Heiss G , Ellison RC , Province MA , Pankow JS , Eckfeldt JH , Hunt SC Coronary artery disease risk in familial combined hyperlipidemia and familial hypertriglyceridemia: a case-control comparison from the National Heart, Lung, and Blood Institute Family Heart Study.

Goldstein JL , Schrott HG , Hazzard WR , Bierman EL , Motulsky AG Hyperlipidemia in coronary heart disease. Genetic analysis of lipid levels in families and delineation of a new inherited disorder, combined hyperlipidemia. J Clin Invest 52 : — Nikkila EA , Aro A Family study of serum lipids and lipoproteins in coronary heart-disease.

Lancet 1 : — Castro Cabezas M , de Bruin TW , Erkelens DW Familial combined hyperlipidaemia: — Austin MA , McKnight B , Edwards KL , Bradley CM , McNeely MJ , Psaty BM , Brunzell JD , Motulsky, AG Cardiovascular disease mortality in familial forms of hypertriglyceridemia: A year prospective study.

Voors-Pette C , de Bruin TW Excess coronary heart disease in familial combined hyperlipidemia, in relation to genetic factors and central obesity. Atherosclerosis : — Rose HG , Kranz P , Weinstock M , Juliano J , Haft JI Inheritance of combined hyperlipoproteinemia: evidence for a new lipoprotein phenotype.

Brunzell JD , Schrott HG , Motulsky AG , Bierman EL Myocardial infarction in the familial forms of hypertriglyceridemia.

Metabolism 25 : — Genest Jr JJ , Martin-Munley SS , McNamara JR , Ordovas JM , Jenner J , Myers RH , Silberman SR , Wilson PW , Salem DN , Schaefer, EJ Familial lipoprotein disorders in patients with premature coronary artery disease.

Circulation 85 : — Chait A , Albers JJ , Brunzell JD Very low density lipoprotein overproduction in genetic forms of hypertriglyceridaemia.

Eur J Clin Invest 10 : 17 — Kissebah AH , Alfarsi S , Adams PW Integrated regulation of very low density lipoprotein triglyceride and apolipoprotein-B kinetics in man: normolipemic subjects, familial hypertriglyceridemia and familial combined hyperlipidemia.

Metabolism 30 : — Brunzell JD , Albers JJ , Chait A , Grundy SM , Groszek E , McDonald GB Plasma lipoproteins in familial combined hyperlipidemia and monogenic familial hypertriglyceridemia. J Lipid Res 24 : — Ayyobi AF , McGladdery SH , McNeely MJ , Austin MA , Motulsky AG , Brunzell JD Small, dense LDL and elevated apolipoprotein B are the common characteristics for the three major lipid phenotypes of familial combined hyperlipidemia.

Arterioscler Thromb Vasc Biol 23 : — Veerkamp MJ , de Graaf J , Bredie SJ , Hendriks JC , Demacker PN , Stalenhoef AF Diagnosis of familial combined hyperlipidemia based on lipid phenotype expression in 32 families: results of a 5-year follow-up study.

Arterioscler Thromb Vasc Biol 22 : — Purnell JQ , Kahn SE , Schwartz RS , Brunzell JD Relationship of insulin sensitivity and ApoB levels to intra-abdominal fat in subjects with familial combined hyperlipidemia. Arterioscler Thromb Vasc Biol 21 : — Bredie SJ , Tack CJ , Smits P , Stalenhoef AF Nonobese patients with familial combined hyperlipidemia are insulin resistant compared with their nonaffected relatives.

Arterioscler Thromb Vasc Biol 17 : — Keulen ET , Voors-Pette C , de Bruin TW Familial dyslipidemic hypertension syndrome: familial combined hyperlipidemia, and the role of abdominal fat mass.

Am J Hypertens 14 : — Keulen ET , Kruijshoop M , Schaper NC , Hoeks AP , de Bruin TW Increased intima-media thickness in familial combined hyperlipidemia associated with apolipoprotein B.

Jarvik GP , Brunzell JD , Austin MA , Krauss RM , Motulsky AG , Wijsman E Genetic predictors of FCHL in four large pedigrees. Influence of ApoB level major locus predicted genotype and LDL subclass phenotype. Arterioscler Thromb 14 : — Bachorik PS , Lovejoy KL , Carroll MD , Johnson CL Apolipoprotein B and AI distributions in the United States, — results of the National Health and Nutrition Examination Survey III NHANES III.

Clin Chem 43 : — Moss AJ , Goldstein RE , Marder VJ , Sparks CE , Oakes D , Greenberg H , Weiss HJ , Zareba W , Brown MW , Liang CS , Lichstein E , Little WC , Gillespie JA , Van Voorhees L , Krone RJ , Bodenheimer MM , Hochman J , Dwyer Jr EM , Arora R , Marcus FI , Watelet LF , Case RB Thrombogenic factors and recurrent coronary events.

Talmud PJ , Hawe E , Miller GJ , Humphries SE Nonfasting apolipoprotein B and triglyceride levels as a useful predictor of coronary heart disease risk in middle-aged UK men.

Grundy SM Non-high-density lipoprotein cholesterol level as potential risk predictor and therapy target. Ginsberg HN Treatment for patients with the metabolic syndrome.

Am J Cardiol 91 : 29 E—39E. Lancet : 7 — Sniderman AD , Furberg CD , Keech A , Roeters van Lennep JE , Frohlich J , Jungner I , Walldius G Apolipoproteins versus lipids as indices of coronary risk and as targets for statin treatment.

Meyers CD , Carr MC , Park S , Brunzell JD Varying cost and free nicotinic acid content in over-the-counter niacin preparations for dyslipidemia. Elam MB , Hunninghake DB , Davis KB , Garg R , Johnson C , Egan D , Kostis JB , Sheps DS , Brinton EA Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: the ADMIT study: a randomized trial.

Arterial Disease Multiple Intervention Trial. Grundy SM , Vega GL , McGovern ME , Tulloch BR , Kendall DM , Fitz-Patrick D , Ganda OP , Rosenson RS , Buse JB , Robertson DD , Sheehan JP Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial.

Zhao XQ , Morse JS , Dowdy AA , Heise N , DeAngelis D , Frohlich J , Chait A , Albers JJ , Brown BG Safety and tolerability of simvastatin plus niacin in patients with coronary artery disease and low high-density lipoprotein cholesterol The HDL Atherosclerosis Treatment Study.

Oxford University Press is a department of the University of Oxford. It furthers the University's objective of excellence in research, scholarship, and education by publishing worldwide.

Sign In or Create an Account. Endocrine Society Journals. Advanced Search. Search Menu. Article Navigation. Close mobile search navigation Article Navigation. Volume Article Contents Abstract. Link between abdominal obesity and metabolic abnormalities. Dyslipidemia of abdominal adiposity.

Prevalence and risk of the metabolic syndrome. Metabolic syndrome: targeting high risk patients. Screening of metabolic syndrome patients. Treatment of dyslipidemia. Journal Article.

Abdominal Obesity and Dyslipidemia in the Metabolic Syndrome: Importance of Type 2 Diabetes and Familial Combined Hyperlipidemia in Coronary Artery Disease Risk. Carr , Molly C. Carr, M. Oxford Academic. John D. PDF Split View Views.

Abdominal abdoimnal, due to intra-abdominal adiposity, obesitt the progression of multiple cardiometabolic risk factors abdomial of body mass index. This occurs both Enhancing sports decision-making altered secretion Enhancing sports decision-making adipocyte-derived biologically syndromf substances adipokinesincluding free fatty acids, adiponectin, interleukin-6, obestiy necrosis Sugar substitutes for diabetics alpha, and plasminogen abdomminal inhibitor-1, and through exacerbation of insulin Metabolic syndrome abdominal obesity and associated cardiometabolic risk factors. The prevalence of abdominal obesity is increasing in western populations, due to a combination of low physical activity and high-energy diets, and also in developing countries, where it is associated with the urbanization of populations. The measurement of waist circumference, together with an additional comorbidity, readily identifies the presence of increased cardiometabolic risk associated with abdominal obesity. Accordingly, measurement of waist circumference should become a standard component of cardiovascular risk evaluation in routine clinical practice. Lifestyle modification remains the initial intervention of choice for this population, with pharmacological modulation of risk factors where this is insufficiently effective. BMC Abdominzl Science, Medicine Enhancing sports decision-making Syndroe volume 10Article Mwtabolic 7 Cite this article. Metrics details. Eyndrome syndrome is Enhancing sports decision-making as Enhancing sports decision-making cluster of at least three out of five clinical risk factors: abdominal visceral obesity, hypertension, elevated serum triglycerides, low serum high-density lipoprotein HDL and insulin resistance. Evidence shows that regular and consistent exercise reduces abdominal obesity and results in favourable changes in body composition. It has therefore been suggested that exercise is a medicine in its own right and should be prescribed as such. This review provides a summary of the current evidence on the pathophysiology of dysfunctional adipose tissue adiposopathy.

Author: Dulmaran

2 thoughts on “Metabolic syndrome abdominal obesity

  1. Ich bin endlich, ich tue Abbitte, aber es kommt mir nicht ganz heran. Wer noch, was vorsagen kann?

Leave a comment

Yours email will be published. Important fields a marked *

Design by